Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
Public ClinicalTrials.gov record NCT04134936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab in Addition to R-CHOP or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - First-MIND
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, randomized, multicentre study to evaluate safety and preliminary efficacy of the human anti-CD19 antibody Tafasitamab in addition to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) or Tafasitamab and Lenalidomide in addition to R-CHOP in adult patients with newly diagnosed, previously untreated Diffuse Large B-cell Lymphoma (DLBCL).
Study identification
- NCT ID
- NCT04134936
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 10, 2019
- Primary completion
- Feb 10, 2021
- Completion
- Aug 9, 2022
- Last update posted
- Oct 15, 2024
2019 – 2022
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MorphoSys Research Site | Tucson | Arizona | 85711 | — |
| MorphoSys Research Site | Anaheim | California | 92801 | — |
| MorphoSys Research Site | Duarte | California | 91010 | — |
| MorphoSys Research Site | Encinitas | California | 92024 | — |
| MorphoSys Research Site | Aurora | Colorado | 80012 | — |
| MorphoSys Research Site | New Haven | Connecticut | 06520 | — |
| MorphoSys Research Site | Washington D.C. | District of Columbia | 20037 | — |
| MorphoSys Research Site | Urbana | Illinois | 61801 | — |
| MorphoSys Research Site | Louisville | Kentucky | 40207 | — |
| MorphoSys Research Site | Covington | Louisiana | 70433 | — |
| MorphoSys Research Site | Rockville | Maryland | 20850 | — |
| MorphoSys Research Site | Ann Arbor | Michigan | 48109-5864 | — |
| MorphoSys Research Site | Rochester | Minnesota | 55905 | — |
| MorphoSys Research Site | Cincinnati | Ohio | 45236 | — |
| MorphoSys Research Site | Cleveland | Ohio | 44106 | — |
| MorphoSys Research Site | Eugene | Oregon | 97401 | — |
| MorphoSys Research Site | Charleston | South Carolina | 29425 | — |
| MorphoSys Research Site | Austin | Texas | 78705 | — |
| MorphoSys Research Site | Dallas | Texas | 75246 | — |
| MorphoSys Research Site | Houston | Texas | 77030 | — |
| MorphoSys Research Site | San Antonio | Texas | 78240 | — |
| MorphoSys Research Site | Tyler | Texas | 75702 | — |
| MorphoSys Research Site | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04134936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2024 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04134936 live on ClinicalTrials.gov.